Pursuant to the agreement, Roche has the exclusive right in the territory to commercialize the company's existing clinical diagnostic testing commercial products; any clinical diagnostic testing commercial products developed under the Immunotherapy, ctDNA
or CDx Testing Development Platforms; and any other products upon mutual agreement.
The issuance of this patent further supports the unique and proprietary technology that differentiates our highly sensitive ctDNA
platform technology," said Lyle Arnold, Ph.
The potential applications of sequencing ctDNA
include screening or diagnosis of cancer, monitoring for progression or relapse, and guiding therapy for a patient with a known cancer diagnosis.
Droplet digital PCR (ddPCR) is a newly developed technique that uses water-oil emulsion droplet technology for highly sensitive, quantitative, reproducible detection of rare target mutations in ctDNA
as well as cDNA copied from ctRNA.
While these approaches hold great promise, a major assumption is that ctDNA
is either rare or absent in the healthy, cancer-free population.
Another assessment examined ctDNA
(circulating tumor DNA) to determine its efficacy in identifying the risk of breast cancer survivor relapse.
In another study, ctDNA
(circulating tumor DNA) was studied for its efficacy in identifying the risk of breast cancer survivor relapse.
Following further treatments with MTET (Multi-targeted Epigenetic therapy), her Guardant 360 was repeated and showed no ctDNA
The hypochromic shift resulting after interaction of the sample with CTDNA
is associated with the contraction of DNA and a change in its conformation whereas hyperchromic shift is shown to cause damage to the double helix of DNA .
FDA approval for its newly launched ctDNA
test named cobas EGFR mutation test V2, first FDA-approved blood based genetic test that detect EGFR gene mutation in NSCLC patients.
The concept behind Grail's proposed blood test--one that they call "The Early Detection ctDNA
Hypothesis"--relies on deep sequencing of ctDNA
The research team found that ctDNA
could detect cancer recurrence, as confirmed by X-ray or CT scan, in 22 of 26 patients tested (85 percent) and undergoing therapy.